The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Opus Genetics Inc (NASDAQ: IRD) closed at $2.01 in the last session, up 0.50% from day before closing price of $2.0. In other words, the price has increased by $0.50 from its previous closing price. On the day, 0.58 million shares were traded. IRD stock price reached its highest trading level at $2.09 during the session, while it also had its lowest trading level at $1.98.
Ratios:
We take a closer look at IRD’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 1.90. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Chardan Capital Markets on October 16, 2025, initiated with a Buy rating and assigned the stock a target price of $9.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 26 ’24 when Magrath George bought 100,000 shares for $0.98 per share. The transaction valued at 97,600 led to the insider holds 599,150 shares of the business.
YERXA BENJAMIN R bought 10,000 shares of IRD for $9,834 on Nov 21 ’24. The President now owns 342,800 shares after completing the transaction at $0.98 per share. On Nov 15 ’24, another insider, Magrath George, who serves as the Chief Executive Officer of the company, bought 90,294 shares for $1.01 each. As a result, the insider paid 91,215 and bolstered with 483,244 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRD now has a Market Capitalization of 120415192 and an Enterprise Value of 88986192. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.81 while its Price-to-Book (P/B) ratio in mrq is 6.89. Its current Enterprise Value per Revenue stands at 5.77 whereas that against EBITDA is -2.416.
Stock Price History:
The Beta on a monthly basis for IRD is 0.10, which has changed by 0.52272725 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, IRD has reached a high of $2.16, while it has fallen to a 52-week low of $0.65. The 50-Day Moving Average of the stock is 35.50%, while the 200-Day Moving Average is calculated to be 74.93%.
Shares Statistics:
According to the various share statistics, IRD traded on average about 305.29K shares per day over the past 3-months and 557420 shares per day over the past 10 days. A total of 59.91M shares are outstanding, with a floating share count of 26.03M. Insiders hold about 56.55% of the company’s shares, while institutions hold 23.10% stake in the company. Shares short for IRD as of 1759190400 were 125683 with a Short Ratio of 0.41, compared to 1756425600 on 54164. Therefore, it implies a Short% of Shares Outstanding of 125683 and a Short% of Float of 0.22.
Earnings Estimates
Currently, 1.0 analysts are dedicated to thoroughly evaluating and rating the performance of Opus Genetics Inc (IRD) in the stock market.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.1 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.6 and -$0.6 for the fiscal current year, implying an average EPS of -$0.6. EPS for the following year is -$0.4, with 1.0 analysts recommending between -$0.4 and -$0.4.
Revenue Estimates
According to 5 analysts,. The current quarter’s revenue is expected to be $3.2M. It ranges from a high estimate of $4M to a low estimate of $2.5M. As of. The current estimate, Opus Genetics Inc’s year-ago sales were $3.87MFor the next quarter, 5 analysts are estimating revenue of $3.61M. There is a high estimate of $4M for the next quarter, whereas the lowest estimate is $3.1M.
A total of 5 analysts have provided revenue estimates for IRD’s current fiscal year. The highest revenue estimate was $15.25M, while the lowest revenue estimate was $13.3M, resulting in an average revenue estimate of $14.07M. In the same quarter a year ago, actual revenue was $10.99MBased on 5 analysts’ estimates, the company’s revenue will be $18.46M in the next fiscal year. The high estimate is $30M and the low estimate is $5M.
